The study tested Trulicity alongside Sanofi’s (4SNY) Lantus (insulin glargine), and the combo beat Lantus alone at every measure. The new data is important “because it adds to the dataset on Trulicity ...
Trulicity was late to the next-generation diabetes treatment party, so Eli Lilly ($LLY) knew its launch would have to be different. The traditional U.S. strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback